Clinical Trial

TearCare MGX™ System With and Without Warming Hold

Study acronym: XTEND
Completed
View on ClinicalTrials.gov →
Summary
TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction. In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).
Protocol Amendment History 2 changes
critical Trial completed 2026-06-06
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-04-25
Trial Details
NCT Number NCT07365735
Lead Sponsor Sight Sciences, Inc.
Conditions Meibomian Gland Dysfunction (Disorder)
Enrollment 21 participants
Start Date 2026-03-17
Primary Completion 2026-05-19 (estimated)
Study Completion 2026-05-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-05